血管体与非血管体靶向腓动脉旁路对慢性肢体威胁性缺血患者保肢与愈合的影响
这项回顾性研究纳入2004至2015年间两中心120例慢性肢体威胁性缺血伴足部组织缺损并接受腓动脉旁路的患者,比较直接(血管体)与间接血运重建的结局。结果发现直接血运重建并未显著改善3年保肢生存或伤口愈合,而腓动脉双分支通畅、足弓通畅及较低WIfI分期与更好的无截肢生存相关。
要点
- 腓动脉旁路术后直接血管体血运重建与间接血运重建的3年无截肢生存无显著差异。
- 腓动脉双分支通畅和足弓通畅是3年无截肢生存的显著预测因素。
- 糖尿病、WIfI分期较高与较差的无截肢生存相关,而血管体靶向并非独立预测因素。
核心结论
- 在慢性肢体威胁性缺血伴组织缺损接受腓动脉旁路的患者中,腓动脉双分支通畅和足弓通畅与更好的伤口愈合率及无截肢生存率相关,与伤口是否位于血管体无关。
研究设计与样本
- 回顾性研究,基于两个欧洲大学中心2004至2015年前瞻性维护的数据库,纳入120例慢性肢体威胁性缺血伴足部组织缺损并接受腓动脉旁路的患者。
主要发现
- 仅55处伤口(46%)可归于腓动脉血管体。
- 直接血运重建组3年无截肢生存为54.9% ± 7.3%,间接组为56.5% ± 6.3%(P = .44),伤口愈合无显著差异。
- 腓动脉双分支通畅者3年无截肢生存为74.8% ± 6.9%,单分支者为45.0% ± 6.0%(P = .003)。
- 足弓通畅(Rutherford 0-1)者3年无截肢生存为73.0% ± 7.0%,足弓不完整(Rutherford 2-3)者为45.7% ± 6.0%(P = .0002)。
- WIfI 1或2级者3年无截肢生存为87.4% ± 8.3%,3或4级者为48.4% ± 5.3%(P = .001);糖尿病患者为43.7% ± 6.2%,非糖尿病者为73.1% ± 6.7%(P = .002)。
临床怎么用
- 腓动脉旁路术后应关注腓动脉分支和足弓的通畅性,而非仅追求血管体靶向血运重建。
- 糖尿病及较高WIfI分期的患者无截肢生存较差,需加强围手术期管理。
局限性
- 回顾性研究设计,样本量有限(120例),仅纳入腓动脉旁路患者,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Direct (DIR) or indirect (IND) revascularization of pedal angiosomes in patients with chronic limb-threatening ischemia (CLTI) has an unclear impact on limb salvage and healing. The aim of this study was to evaluate the outcomes of DIR and IND revascularization in patients with a peroneal bypass and tissue loss. METHODS: We conducted a retrospective study of a prospectively maintained database in two European university centers from 2004 to 2015. We extracted from this database all patients with CLTI and tissue loss who had received a bypass to the peroneal artery. All patients underwent angiography before bypass. Revascularization was considered DIR if the wound was in a peroneal angiosome. Wounds, ischemia, and infection were categorized according to the Wound, Ischemia, and foot Infection (WIfI) classification. Limb salvage and amputation-free survival were calculated using the Kaplan-Meier method. Cox regression was used to compare the role of patient characteristics, including diabetes, peroneal runoff, pedal arch angiosome, WIfI grade, chronic kidney disease, and diabetes, in amputation-free-survival. RESULTS: From January 2004 through October 2015, there were 120 peroneal bypasses performed in 120 patients with CLTI and foot tissue loss. Only 55 wounds (46%) could be ascribed to a peroneal angiosome. At 3 years, amputation-free survival in patients with DIR revascularization was 54.9% ± 7.3% compared with 56.5% ± 6.3% in patients with IND revascularization (P = .44), with no significant difference in wound healing. Amputation-free survival at 3 years in patients with two patent peroneal branches was 74.8% ± 6.9% compared with 45.0% ± 6.0% in patients with one patent peroneal branch (P = .003). Amputation-free survival at 3 years in patients with a patent pedal arch (Rutherford 0-1) was 73.0% ± 7.0% vs 45.7% ± 6.0% in patients with incomplete pedal arch (Rutherford 2-3; P = .0002). Amputation-free survival at 3 years in patients with grade 1 or grade 2 WIfI was 87.4% ± 8.3% compared with 48.4% ± 5.3% in patients with grade 3 or grade 4 WIfI (P = .001). Amputation-free survival at 3 years in patients with diabetes was 43.7% ± 6.2% compared with 73.1% ± 6.7% in patients without diabetes (P = .002). Wound healing at 6 months was not significantly improved by its location within or outside a peroneal angiosome. Cox regression analysis demonstrated that diabetes, patency of both peroneal branches, patency of pedal arch, and WIfI stage but not DIR angiosome revascularization were significant predictors of amputation-free survival. CONCLUSIONS: Our results suggest that in patients with CLTI and tissue loss receiving a peroneal bypass, patency of both peroneal branches and pedal arch was associated with a better healing rate and a better amputation-free survival rate irrespective of wound angiosome location.
引用
- Ricco JB, Gargiulo M, Stella A, et al. Impact of angiosome- and nonangiosome-targeted peroneal bypass on limb salvage and healing in patients with chronic limb-threatening ischemia. J Vasc Surg. 2017. PMID: 28756043. doi:10.1016/j.jvs.2017.04.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。